Molecular POC Makes Strides

Molecular POC Makes Strides

Six companies to watch in the development of rapid and small footprint DNA testing near patient.


Molecular Diagnostics Faces Competition for Future Point of Care Testing in Developing World

Molecular Diagnostics Faces Competition for Future Point of Care Testing in Developing World

The sensitivity and specificity of nucleic acid analytes provide molecular diagnostics key advantages in clinical practice, particularly in critical health situations. Nucleic acid amplification (NAATs) or molecular tests are now open to routine and distributed use in healthcare thanks to advancements in microfluidics and molecular reagents. As molecular diagnostics enter point-of-care (POC) settings, cost becomes a key issue in comparison to predominantly used and cheaply performed rapid immunoassays.


How Big is the Point-of-Care Diagnostics Market? $18 Billion and Climbing

Our new report finds lots of activity and opportunity in near patient testing. The POC diagnostic industry is part of a paradigm shift from curative medicine to predictive, personalized and preemptive medicine as emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices are transforming the POC landscape. New technologies are making the concept more viable than ever.


KI Webinar Review – How Danaher’s Acquisition of Cepheid Could Shape the Molecular POC Market

KI Webinar Review – How Danaher’s Acquisition of Cepheid Could Shape the Molecular POC Market

Kalorama Information received several questions following its recent webinar regarding the molecular point-of-care (POC) in vitro diagnostics market segment and impact of recent industry M&A activity, especially Danaher’s acquisition of Cepheid. Due to the volume of questions and the time constraint of the webinar’s Q&A session, we were unable to provide live answers to all questions. This blog post addresses several related questions from the webinar and elaborates on another recent post regarding Danaher and Cepheid.


Join Kalorama Information on September 22 for Our Live Webinar “State of the IVD Market in 2016”

Join Kalorama Information on September 22 for Our Live Webinar “State of the IVD Market in 2016”

Kalorama Information publisher Bruce Carlson and IVD market analyst Emil Salazar will host the webinar at 2pm EST on September 22. Interested listeners should register for the event using the link provided in this post.


Cepheid is Danaher’s Key to Unlocking New Markets in Molecular Diagnostics

Cepheid is Danaher’s Key to Unlocking New Markets in Molecular Diagnostics

Kalorama Information offers market research reports relevant to this industry merger with The Market and Potential for Molecular Point of Care Diagnostics and The World Market for Cancer Diagnostics.

For an in vitro diagnostics (IVD) heavyweight, Danaher Corporation had uneven exposure to the molecular diagnostics market, one of the most dynamic and highest growing IVD market segments. Danaher’s recently announced near $4 billion acquisition of molecular diagnostics leader Cepheid effectively closes the gap in diagnostic coverage and introduces the conglomerate to key markets such as...


Envisioning an Essential Diagnostics List (EDL) and Its IVD Market Impact

Envisioning an Essential Diagnostics List (EDL) and Its IVD Market Impact

Kalorama Information offers relevant market research in the areas of molecular point-of-care (POC) diagnostics , traditional POC diagnostics , and physician office laboratory (POL) test markets. Market information in this post was drawn from the associated reports.

In a recent article of the New England Journal of Medicine (NEJM), health and medical experts convincingly argued for the establishment of an Essential Diagnostics List (EDL) modeled on the existing Essential Medicines List (EML). T...


Luminex Acquisition of Nanosphere Continues Trend of Investment in Decentralized Molecular Testing

Luminex Acquisition of Nanosphere Continues Trend of Investment in Decentralized Molecular Testing

This blog post reviews the recent history of acquisitions and investment in the area of decentralized molecular diagnostics. Kalorama Information’s The Market and Potential for Molecular Point of Care Diagnostics provides the current market, projected future sales and total available markets in 2020 for molecular POC diagnostics for flu, strep A, RSV, CT/NG, group B strep (GBS), HPV, HSV, vaginitis, HIV, TB, hepatitis, malaria and many other disease areas.

On May 16, Luminex Corporation announ...


Cepheid, Others Look Beyond Respiratory Infections in the Molecular POC Diagnostics Market

Companies looking beyond the clinical lab in the molecular diagnostics market predominately target rapid test demand in primary care and critical care, chiefly respiratory infections. All CLIA waivers to date for molecular tests have been for respiratory infections (influenza, strep A, RSV), though equally ample and more promising markets for molecular point-of-care (POC) diagnostics market will be found in other areas - including women’s health/sexual health and high-burden diseases in the deve...


qPCR? dPCR? From Anywhere? They’ve Got an App for That in Infectious Disease Testing

qPCR? dPCR? From Anywhere? They’ve Got an App for That in Infectious Disease Testing

This blog post reviews molecular point-of-care (POC) diagnostic platforms included in the most recent edition of the report The Market and Potential for Molecular Point of Care Diagnostics. Kalorama Information offers related titles with qPCR and dPCR Markets , The World Market for Infectious Disease Diagnostic Tests , and The World Market for Molecular Diagnostics.

Contributing a high amount of growth to the clinical IVD market over the past decade, molecular diagnostics is established in ref...